Table 7 Significant correlations between the measures of prevalence of APOBEC-like motifs or kataegis clusters and drug sensitivity
Motif | Measure | Agent | n | ρ | p | p adj | Cancer type |
|---|---|---|---|---|---|---|---|
T(C>K)W | Total number of motifs | WZ3105 | 5 | 1.000 | 1.40 × 10−24 | 5.15 × 10−22 | OVARIAN |
T(C>K)W | Total number of motifs | XMD15-27 | 5 | −1.000 | 1.40 × 10−24 | 5.15 × 10−22 | OVARIAN |
T(C>K)W | Total number of motifs | Tipifarnib | 5 | 1.000 | 1.40 × 10−24 | 5.15 × 10−22 | PAAD |
T(C>K)W | Total number of motifs | AKT inhibitor VIII | 5 | −1.000 | 1.40 × 10−24 | 5.15 × 10−22 | PAAD |
T(C>K)W | Total number of motifs | GSK-1904529A | 5 | 1.000 | 1.40 × 10−24 | 5.15 × 10−22 | PAAD |
T(C>D)R | Total number of motifs | rTRAIL | 6 | −1.000 | < 4.95 × 10−324 | < 4.95 × 10−324 | OVARIAN |
T(C>D)R | Total number of motifs | WZ3105 | 5 | 1.000 | 1.40 × 10−24 | 3.22 × 10−22 | OVARIAN |
T(C>D)R | Total number of motifs | XMD15-27 | 5 | −1.000 | 1.40 × 10−24 | 3.22 × 10−22 | OVARIAN |
T(C>D)R | Total number of motifs | KIN001-266 | 5 | −1.000 | 1.40 × 10−24 | 3.22 × 10−22 | COAD/READ |
T(C>D)R | Total number of motifs | BMS-536924 | 5 | −1.000 | 1.40 × 10−24 | 3.22 × 10−22 | GLIOMA |
T(C>D)R | Total number of motifs | HG-5-113-01 | 5 | 1.000 | 1.40 × 10−24 | 3.22 × 10−22 | BREAST |
T(C>D)R | Total number of motifs | Vismodegib | 5 | −1.000 | 1.40 × 10−24 | 3.22 × 10−22 | PAAD |
T(C>D)R | Total number of motifs | FH535 | 5 | −1.000 | 1.40 × 10−24 | 3.22 × 10−22 | PAAD |
T(C>D)D | Total number of motifs | rTRAIL | 6 | −1.000 | < 4.95 × 10−324 | < 4.95 × 10−324 | OVARIAN |
T(C>D)D | Total number of motifs | WZ3105 | 5 | 1.000 | 1.40 × 10−24 | 3.22 × 10−22 | OVARIAN |
T(C>D)D | Total number of motifs | XMD15-27 | 5 | −1.000 | 1.40 × 10−24 | 3.22 × 10−22 | OVARIAN |
T(C>D)D | Total number of motifs | NVP-BEZ235 | 5 | −1.000 | 1.40 × 10−24 | 3.22 × 10−22 | COAD/READ |
T(C>D)D | Total number of motifs | T0901317 | 5 | −1.000 | 1.40 × 10−24 | 3.22 × 10−22 | COAD/READ |
T(C>D)D | Total number of motifs | RDEA119 | 5 | −1.000 | 1.40 × 10−24 | 3.22 × 10−22 | COAD/READ |
T(C>D)D | Total number of motifs | HG-5-113-01 | 5 | 1.000 | 1.40 × 10−24 | 3.22 × 10−22 | BREAST |
T(C>D)D | Total number of motifs | LY317615 | 5 | 1.000 | 1.40 × 10−24 | 3.22 × 10−22 | PAAD |
T(C>D)D | Length of kataegis regions | PF-4708671 | 6 | 1.000 | < 4.95 × 10−324 | < 4.95 × 10−324 | BREAST |
T(C>D)D | Length of kataegis regions | EX-527 | 5 | −1.000 | 1.40 × 10−24 | 2.15 × 10−22 | COAD/READ |
T(C>D)D | Length of kataegis regions | KIN001-236 | 5 | −1.000 | 1.40 × 10−24 | 2.15 × 10−22 | COAD/READ |
T(C>D)D | Length of kataegis regions | CAL-101 | 5 | −1.000 | 1.40 × 10−24 | 2.15 × 10−22 | COAD/READ |
T(C>D)D | Length of kataegis regions | Y-39983 | 5 | −1.000 | 1.40 × 10−24 | 2.15 × 10−22 | COAD/READ |
T(C>D)D | Length of kataegis regions | KIN001-270 | 5 | −1.000 | 1.40 × 10−24 | 2.15 × 10−22 | COAD/READ |
T(C>D)D | Length of kataegis regions | Ruxolitinib | 5 | −1.000 | 1.40 × 10−24 | 2.15 × 10−22 | COAD/READ |
T(C>D)D | Length of kataegis regions | XMD14-99 | 5 | −1.000 | 1.40 × 10−24 | 2.15 × 10−22 | COAD/READ |
T(C>D)D | Length of kataegis regions | QL-VIII-58 | 5 | 1.000 | 1.40 × 10−24 | 2.15 × 10−22 | BREAST |
T(C>D)D | Length of kataegis regions | Genentech Cpd 10 | 5 | 1.000 | 1.40 × 10−24 | 2.15 × 10−22 | PAAD |
T(C>D)D | Length of kataegis regions | Gemcitabine | 5 | 1.000 | 1.40 × 10−24 | 2.15 × 10−22 | PAAD |
T(C>D)D | Length of kataegis regions | Bicalutamide | 5 | 1.000 | 1.40 × 10−24 | 2.15 × 10−22 | PAAD |
T(C>D)D | Length of kataegis regions | Bicalutamide | 7 | 0.991 | 1.46 × 10−5 | 0.0021 | BREAST |